Molecular Formula | C9H5N3O2 |
Molar Mass | 187.15 |
Density | 1.3753 (rough estimate) |
Melting Point | 160-170 °C |
Boling Point | 321.89°C (rough estimate) |
Solubility | ethanol: 1.2mg/mL |
Appearance | powder |
Color | pale yellow |
pKa | 0.94±0.20(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
Refractive Index | 1.6500 (estimate) |
In vitro study | At 30 and 50 μM, ODQ causes significant induction of apoptosis in the NCI-H2452 cells, elevating apoptotic levels by 12 fold and 15 fold, respectively. At 10μM, a concentration below the threshold for induction of apoptosis by ODQ, ODQ in combination with Cisplatin enhanced (in fact, doubled) the pro-apoptotic effects of Cisplatin at 1 μM. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
RTECS | RO0913150 |
HS Code | 29349990 |
Biological activity | ODQ (1H-ODQ) is an effective and selective inhibitor of soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme), which can enhance the pro-apoptotic effect of cisplatin in human mesothelioma cells. |
Target | Value |
Animal Model: | Anesthetized, male Wistar rats |
Dosage: | 2 mg/kg |
Administration: | I.p. |
Result: | Attenuated the renal dysfunction, lung injury, and hepatocellular injury caused by lipoteichoic acid/peptidoglycan or lipopolysaccharide. |